BR112015004463A2 - dispositivo hiperbárico e processos para produzir vacinas inativadas e para redobrar/solubilizar proteínas recombinantes - Google Patents

dispositivo hiperbárico e processos para produzir vacinas inativadas e para redobrar/solubilizar proteínas recombinantes

Info

Publication number
BR112015004463A2
BR112015004463A2 BR112015004463A BR112015004463A BR112015004463A2 BR 112015004463 A2 BR112015004463 A2 BR 112015004463A2 BR 112015004463 A BR112015004463 A BR 112015004463A BR 112015004463 A BR112015004463 A BR 112015004463A BR 112015004463 A2 BR112015004463 A2 BR 112015004463A2
Authority
BR
Brazil
Prior art keywords
processes
hyperbaric
producing
proteins
inactivated
Prior art date
Application number
BR112015004463A
Other languages
English (en)
Other versions
BR112015004463B8 (pt
BR112015004463B1 (pt
Inventor
Merian Gildas
Gerentes Lionel
Pierre Yves Carboulec Nicolas
Labatut René
Original Assignee
Merial Inc
Top Ind S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc, Top Ind S A S filed Critical Merial Inc
Publication of BR112015004463A2 publication Critical patent/BR112015004463A2/pt
Publication of BR112015004463B1 publication Critical patent/BR112015004463B1/pt
Publication of BR112015004463B8 publication Critical patent/BR112015004463B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/015—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with pressure variation, shock, acceleration or shear stress or cavitation
    • A23L3/0155—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with pressure variation, shock, acceleration or shear stress or cavitation using sub- or super-atmospheric pressures, or pressure variations transmitted by a liquid or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y201/00—Transferases transferring one-carbon groups (2.1)
    • C12Y201/01—Methyltransferases (2.1.1)
    • C12Y201/01041—Sterol 24-C-methyltransferasee (2.1.1.41)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

resumo da patente de invenção para: “dispositivo hiperbárico e processos para produzir vacinas inativadas e para redobrar/solubilizar proteínas recombinantes”. a invenção se refere a dispositivos hiperbáricos para inativar microrganismos e vírus, preservando a imunogenicidade dos mesmos, e para fazer e produzir as proteínas imunogênicas ou terapêuticas solúveis, desagregadas, redobradas ou ativas a partir dos corpos de inclusão produzidos a partir de procariotos ou eucariotos. a invenção engloba métodos hiperbáricos para inativar organismos patogênicos e processos para a produção de composições de vacina usando os patógenos inativados. os microrganismos hiperbaricamente inativados são mais seguros e mais imunogênicos do que os microrganismos quimicamente inativados. da mesma forma, as proteínas solubilizadas têm propriedades superiores em comparação com as proteínas mais fortemente agregadas, incluindo um grau reduzido de reações imunológicas não específicas.
BR112015004463A 2012-08-30 2013-08-30 Dispositivo hiperbárico e processos para produzir vacinas inativadas e para redobrar/solubilizar proteínas recombinantes BR112015004463B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261694968P 2012-08-30 2012-08-30
US61/694,968 2012-08-30
US201361830425P 2013-06-03 2013-06-03
US61/830,425 2013-06-03
PCT/US2013/057426 WO2014036345A2 (en) 2012-08-30 2013-08-30 Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins

Publications (3)

Publication Number Publication Date
BR112015004463A2 true BR112015004463A2 (pt) 2017-08-08
BR112015004463B1 BR112015004463B1 (pt) 2021-08-24
BR112015004463B8 BR112015004463B8 (pt) 2022-06-28

Family

ID=49162270

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015004463A BR112015004463B8 (pt) 2012-08-30 2013-08-30 Dispositivo hiperbárico e processos para produzir vacinas inativadas e para redobrar/solubilizar proteínas recombinantes

Country Status (18)

Country Link
US (3) US9315553B2 (pt)
EP (2) EP2890393A2 (pt)
JP (2) JP6405308B2 (pt)
KR (1) KR102208844B1 (pt)
CN (3) CN104768577B (pt)
AP (1) AP2015008331A0 (pt)
AU (4) AU2013308623B2 (pt)
BR (1) BR112015004463B8 (pt)
CA (2) CA2883296A1 (pt)
EA (1) EA031988B1 (pt)
ES (1) ES2744709T3 (pt)
HK (2) HK1211873A1 (pt)
MD (1) MD4608C1 (pt)
MX (3) MX2015002701A (pt)
NZ (3) NZ715459A (pt)
PH (1) PH12015500700B1 (pt)
RU (1) RU2647568C2 (pt)
WO (2) WO2014036345A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968749B2 (en) * 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
AU2013308623B2 (en) 2012-08-30 2017-03-02 Merial, Inc. Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
ZA201501696B (en) 2012-08-30 2016-01-27 Merial Ltd Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
WO2014160987A2 (en) 2013-03-28 2014-10-02 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
CN104758944B (zh) * 2015-04-02 2017-11-28 中国科学院过程工程研究所 一种疫苗制剂及其制备方法和用途
JP2018082987A (ja) * 2016-11-25 2018-05-31 株式会社日立製作所 ウイルス不活化方法及びウイルス不活化装置
JP2020152644A (ja) * 2019-03-18 2020-09-24 国立大学法人愛媛大学 Ｖｎａｒのリフォールディング方法およびｖｎａｒの製造方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
CN112120012B (zh) * 2020-09-30 2022-03-22 广东康盾创新产业集团股份公司 一种car-t细胞冻存方法
BR102021000794A2 (pt) * 2021-01-15 2022-07-26 Fundação Oswaldo Cruz Proteína quimérica, kit, método para diagnóstico de leishmaniose, uso de uma proteína quimérica, composição vacinal contra leishmaniose visceral, e, uso de uma composição vacinal

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
JP2743177B2 (ja) * 1987-04-24 1998-04-22 財団法人阪大微生物病研究会 百日咳菌の培養方法、及び百日咳トキソイドとその混合ワクチン
DE69733020T2 (de) 1996-10-11 2006-02-16 The Regents Of The University Of California, Oakland Immunostimulierende oligonucleotidekonjugate
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
FR2771011B1 (fr) 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
DK1095056T3 (da) 1998-07-09 2007-04-23 Barofold Inc Höjtryksrefoldning af proteinaggregater og inklusionslegemer
EP1180945A1 (en) 1999-05-28 2002-02-27 Universite Laval Inactivation of food spoilage and pathogenic microorganisms by dynamic high pressure
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
MXPA02003108A (es) 1999-09-25 2003-10-14 Univ Iowa Res Found Acidos nucleicos inmunoestimuladores.
US7615617B2 (en) 1999-10-25 2009-11-10 University Of Delaware Use of hydrostatic pressure to inhibit and reverse protein aggregation and facilitate protein refolding
WO2002056824A2 (en) 2000-08-10 2002-07-25 Boston Biomedica, Inc. Pressure cycling inactivation of pathogens in biological materials used for therapeutics or vaccines
US6635223B2 (en) * 2000-10-25 2003-10-21 Andreas Maerz Method for inactivating micro-organisms using high pressure processing
EP1434789B1 (en) 2000-10-31 2008-03-26 BaroFold, Inc. Improved protein disaggregation and refolding using high pressure
AU2003245416A1 (en) 2002-06-07 2004-04-30 University Of Florida Endodontic files made using bulk metallic glasses
SE525457C2 (sv) 2002-06-24 2005-02-22 Flow Holdings Sagl Förfarande för åstadkommande av en tryckändring mellan två trycktillstånd, högtryckspressanordning samt användning av förfarande eller högtryckspressanordning
RS52507B (en) * 2003-11-05 2013-04-30 Laboratorios Leti S.L. APPLICATION OF SPECIFIC HISTONS FOR THE TREATMENT OF PARASITIC DISEASES
US7993580B2 (en) 2004-08-24 2011-08-09 Baxter International Inc. Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
EP1971435A2 (en) 2005-11-21 2008-09-24 BaroFold, Inc. Devices and methods for high-pressure refolding of proteins
CN200945252Y (zh) * 2006-09-01 2007-09-12 天津市华泰森淼生物工程技术有限公司 手动开启式小型超高压生物处理设备
US20080161242A1 (en) * 2006-09-15 2008-07-03 Randolph Theodore W High pressure treatment of proteins for reduced immunogenicity
US7829681B2 (en) * 2007-04-05 2010-11-09 Barofold Inc. High-pressure inclusion body solubilization and protease clipping of recombinant fusion proteins
US20080249286A1 (en) 2007-04-05 2008-10-09 Seefeldt Matthew B High-pressure refolding of proteins in the presence of binding partners
WO2009045553A1 (en) 2007-10-05 2009-04-09 Barofold, Inc. High pressure treatment of aggregated interferons
NZ585877A (en) * 2007-12-21 2012-06-29 Pfizer Heat treated bacterins, and emulsion vaccines prepared from such heat treated bacterins
BRPI0800357A2 (pt) 2008-03-10 2009-10-27 Fundacao Oswaldo Cruz método para produção de uma vacina estabilizada
BRPI0915605B8 (pt) 2008-05-08 2021-09-08 The Government Of The Us Secretary Of The Dept Of Healt & Human Services Vacina de leishmania usando imunógeno salivar de mosca tipo borrachudo
US8410258B2 (en) * 2008-05-21 2013-04-02 Infections Disease Research Institute Recombinant polyprotein vaccines for the treatment and diagnosis of leishmaniasis
AR073170A1 (es) 2008-05-21 2010-10-20 Infectious Disease Res Inst Vacunas de poliproteinas recombinantes para el tratamiento y diagnostico de leishmaniasis
US20100112660A1 (en) 2008-05-30 2010-05-06 Barofold, Inc. Method for Derivatization of Proteins Using Hydrostatic Pressure
US20110070219A1 (en) 2009-04-27 2011-03-24 Seefeldt Matthew B High pressure protein crystallization
EP2531042A1 (en) * 2010-02-01 2012-12-12 Avure Technologies AB High-pressure arrangement with locking element preventing rotation of load basket
CN201781934U (zh) * 2010-04-14 2011-04-06 中国农业大学 一种小型框架自动式超高压设备
WO2012012388A2 (en) 2010-07-19 2012-01-26 Barofold, Inc. Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy
ZA201501696B (en) * 2012-08-30 2016-01-27 Merial Ltd Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins
AU2013308623B2 (en) * 2012-08-30 2017-03-02 Merial, Inc. Hyperbaric device and methods for producing inactivated vaccines and for refolding/solubilizing recombinant proteins

Also Published As

Publication number Publication date
AU2017200301A1 (en) 2017-02-16
ES2744709T3 (es) 2020-02-26
MX358782B (es) 2018-09-04
CA2883303A1 (en) 2014-03-06
EP2890392B1 (en) 2019-04-17
EA201500275A1 (ru) 2015-07-30
US20140065187A1 (en) 2014-03-06
KR102208844B1 (ko) 2021-01-27
MD20150031A2 (ro) 2015-10-31
WO2014036345A2 (en) 2014-03-06
NZ715459A (en) 2017-05-26
PH12015500700A1 (en) 2015-05-25
US10364274B2 (en) 2019-07-30
EP2890393A2 (en) 2015-07-08
JP6438396B2 (ja) 2018-12-12
CN104717976A (zh) 2015-06-17
US9169302B2 (en) 2015-10-27
US9315553B2 (en) 2016-04-19
MD4608B1 (ro) 2018-12-31
MX2021004478A (es) 2021-06-04
AP2015008331A0 (en) 2015-03-31
HK1211873A1 (en) 2016-06-03
MX2015002701A (es) 2015-12-01
AU2013308627B2 (en) 2016-10-27
US20170081372A1 (en) 2017-03-23
BR112015004463B8 (pt) 2022-06-28
EA031988B1 (ru) 2019-03-29
RU2647568C2 (ru) 2018-03-16
CA2883296A1 (en) 2014-03-06
JP2015529462A (ja) 2015-10-08
MD4608C1 (ro) 2019-07-31
AU2013308623B2 (en) 2017-03-02
NZ706288A (en) 2016-06-24
CN108578679A (zh) 2018-09-28
JP6405308B2 (ja) 2018-10-17
RU2015111255A (ru) 2016-10-20
AU2017201724A1 (en) 2017-03-30
MX2015002699A (es) 2015-12-01
PH12015500700B1 (en) 2015-05-25
HK1211874A1 (en) 2016-06-03
AU2013308623A1 (en) 2015-04-02
JP2015528466A (ja) 2015-09-28
EP2890392A1 (en) 2015-07-08
WO2014036349A1 (en) 2014-03-06
NZ705790A (en) 2016-06-24
AU2017201724B2 (en) 2019-01-17
AU2013308627A1 (en) 2015-04-09
BR112015004463B1 (pt) 2021-08-24
KR20150063403A (ko) 2015-06-09
US20140072594A1 (en) 2014-03-13
WO2014036345A3 (en) 2014-06-26
CN104768577B (zh) 2020-06-09
CN104768577A (zh) 2015-07-08

Similar Documents

Publication Publication Date Title
BR112015004463A2 (pt) dispositivo hiperbárico e processos para produzir vacinas inativadas e para redobrar/solubilizar proteínas recombinantes
MX2019004913A (es) Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
BR112014024159A2 (pt) Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
BR112012030337A2 (pt) vacinas compreendendo colesterol e cpg como moléculas veículo-adjuvante exclusivas e uso das mesmas
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201391515A1 (ru) Инактивированная вакцина вируса денге
BR112013011194A2 (pt) partículas de glicoproteína semelhantes a vírus (vlps) da raiva.
EA201501033A1 (ru) Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
EA201290956A1 (ru) Вакцина против вич
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
MX351380B (es) Composiciones y metodos de vacuna de tipo ib de virus de diarrea viral de bovino.
MX2015007753A (es) Composicion de vacunas para sujetos intactos.
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
BR112023022928A2 (pt) Composição imunogênica contra gripe
EA201491845A1 (ru) Получение стерильных активных фармацевтических ингредиентов
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
MX2014014521A (es) Vacuna de virus de schmallenberg (sbv), metodos de produccion y sus usos.
EA201301300A2 (ru) Фармацевтическая композиция в форме пероральной суспензии, которая содержит фракцию флавоноида и ксантановую камедь

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B12F Other appeals [chapter 12.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICA-SE A PUBLICACAO DO PARECER DE DEFERIMENTO DA RPI 2631 DE 08/06/2021, TENDO EM VISTA QUE FOI EFETUADO COM INCORRECAO.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/08/2013, OBSERVADAS AS CONDICOES LEGAIS.

B25G Requested change of headquarter approved

Owner name: MERIAL, INC. (US) ; TOP INDUSTRIE S.A.S. (FR)

B25A Requested transfer of rights approved

Owner name: TOP INDUSTRIE S.A.S. (FR) ; BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)